ATUL2024-10-012024-12-31 ATUL2024-10-012024-12-31 ATUL2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ATUL2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member ATUL2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ATUL2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member ATUL2024-12-31 ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue03Member ATUL2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member ATUL2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member ATUL2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue03Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults03Member ATUL2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member ATUL2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member ATUL2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults03Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets03Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member ATUL2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member ATUL2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member ATUL2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member ATUL2024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member ATUL2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ATUL2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ATUL2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member ATUL2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ATUL2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ATUL2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member ATUL2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ATUL2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member ATUL2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss03Member ATUL2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member ATUL2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member ATUL2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500027 ATUL NOTLISTED Atul Limited Equity 2024-04-01 2025-03-31 2025-01-24 2024-12-24 INR Crores Third quarter 10:30:00 14:30:00 2025-01-24 2025-01-24 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 14168300000.00 157700000.00 14326000000.00 6756900000.00 170500000.00 81200000.00 1124200000.00 42900000.00 809900000.00 3794900000.00 12780500000.00 1545500000.00 0.00 1545500000.00 407000000.00 400000.00 407400000.00 0.00 1138100000.00 0.00 0.00 0.00 32900000.00 1171000000.00 -526900000.00 644100000.00 1087400000.00 83600000.00 -526900000.00 0.00 294400000.00 10 36.93 36.93 0.00 0.00 36.93 36.93 1. These results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on January 23, 2025 and approved by the Board of Directors in its meeting held on January 24, 2025. The Statutory Auditors have carried out a limited review of the consolidated unaudited financial results for the quarter | nine months ended on December 31, 2024. Their limited review report does not have any modification. 3. The Company has reported segment information as per the Ind AS 108, 'Operating Segments', as below: Name of segment Main product groups Life Science Chemicals Active pharmaceutical ingredients and its intermediates, crop protection chemicals Performance and Other Chemicals Adhesion promoters, bulk chemicals, epoxy resins and hardeners, intermediates, textile dyes Others Agribiotech, food products, services and others 4. Other expenses for the quarter include, ` 15.97 cr (` 16.80 cr for the nine months ended on December 31, 2024) incurred towards application fees, cess, premium, conversion charges, customary penal charges, non-agricultural assessment charges, differential stamp duty, etc, for converting part of the agricultural land to industrial use. Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 41317100000.00 603300000.00 41920400000.00 20960000000.00 454500000.00 -1263300000.00 3357400000.00 185600000.00 2351100000.00 10908200000.00 36953500000.00 4966900000.00 0.00 4966900000.00 1208400000.00 168600000.00 1377000000.00 0.00 3589900000.00 0.00 0.00 0.00 97100000.00 3687000000.00 2516500000.00 6203500000.00 3574300000.00 112700000.00 2516500000.00 0.00 294400000.00 10 121.40 121.40 0.00 0.00 121.40 121.40 Other Expenses 2017100000.00 Power, fuel and water 1777800000.00 Other Expenses 5885000000.00 Power, fuel and water 5023200000.00 Life Science Chemicals 4164000000.00 Others 187400000.00 Performance and other chemicals 10412200000.00 Life Science Chemicals 12477800000.00 Others 567800000.00 Performance and other chemicals 30035200000.00 14763600000.00 43080800000.00 14763600000.00 43080800000.00 Life Science Chemicals 956400000.00 Others 33900000.00 Performance and other chemicals 752300000.00 Life Science Chemicals 2502100000.00 Others 110900000.00 Performance and other chemicals 2593400000.00 1742600000.00 5206400000.00 42900000.00 185600000.00 121300000.00 -43200000.00 1578400000.00 5064000000.00 Life Science Chemicals 13345400000.00 Others 2206100000.00 Performance and other chemicals 37121800000.00 52673300000.00 17882300000.00 70555600000.00 Life Science Chemicals 2777200000.00 Others 219800000.00 Performance and other chemicals 6879100000.00 9876100000.00 3430500000.00 13306600000.00 Fair value of equity instruments through other comprehensive income -561500000.00 Remeasurement gain I (loss) on defined benefit plans -1100000.00 Income tax related to items above 86100000.00 Fair value of equity instruments through other comprehensive income 2944900000.00 Remeasurement gain I (loss) on defined benefit plans 18300000.00 Income tax related to items above -482700000.00 -476500000.00 2480500000.00 0.00 0.00 Effective portion of gain I (loss) on cash flow hedges -8300000.00 Exchange differences on translation of foreign operations -41700000.00 Income tax related to items above -400000.00 Effective portion of gain I (loss) on cash flow hedges -10500000.00 Exchange differences on translation of foreign operations 36900000.00 Income tax related to items above 9600000.00 -50400000.00 36000000.00 0.00 0.00